Significant decrease in in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007


Posted at the Zurich Open Repository and Archive, University of Zurich. http://www.zora.uzh.ch

Significant decrease in in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007

Abstract

OBJECTIVES: To evaluate the in-hospital outcome of STEMI (ST elevation myocardial infarction) patients admitted to Swiss hospitals between 2000 and December 2007, and to identify the predictors of in-hospital mortality and major cardiac events. METHODS: Data from the Swiss national registry AMIS Plus (Acute Myocardial Infarction and Unstable Angina in Switzerland) were used. All patients admitted between January 2000 and December 2007 with STEMI or a new LBBB (left bundle branch block) were included in the registry. RESULT: We studied 12 026 STEMI patients admitted to 68 hospitals. The mean age was 64 +/- 13 years and 73% of the patients were male. Incidence of in-hospital death was 7.6% in 2000 and 6% in 2007. Reinfarction fell from 3.7% in 2000 to 0.9% in 2007. Thrombolysis decreased from 40.2% in 2000 to 2% in 2007. Clinical predictors of mortality were: age >65 years, Killips class III or IV, diabetes, Q wave myocardial infarction (at presentation). Patients undergoing percutaneous coronary intervention (PCI) had lower mortality and reinfarction rates (3.9% versus 11.2% and 1.1% versus 3.1% respectively, p <0.001) over time, although their numbers increased from 43% in 2000 to 85% in 2007. Patients admitted to hospitals with PCI facilities had lower mortality than patients hospitalised in hospitals without it, but the demographic characteristics differ widely between the two groups. Both in-hospital mortality and reinfarction decreased significantly over the time, parallel to an increased number of PCI. PCI was also the strongest predictor of survival. CONCLUSION: In-hospital mortality and reinfarction rate have decreased significantly in Swiss STEMI patients in the last seven years, parallel to a significant increase in the number of percutaneous coronary interventions in addition to medical therapy. Outcome is not related to the site of admission but to PCI access.
Significant decrease in in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007

Results from the AMIS registry

Valérie Stolt Steiger1, Jean-Jacques Goy1, Jean-Christophe Stauffer2, Dragana Radovanovic3, Nicole Duvoisin4, Philip Urban1, Osmund Bertel1, Paul Erne5 for the AMIS Plus Investigators

1 Division of Cardiology, Hôpital Cantonal, Fribourg, Switzerland
2 AMIS Plus Data Center, Institute for Social and Preventive Medicine, Zürich University, Switzerland
3 Cardiovascular Department, Hôpital de la Tour, Meyrin, Switzerland
4 Division of Cardiology, Triemli Spital, Zürich, Switzerland
5 Division of Cardiology, Kantonspital, Luzern, Switzerland
6 Acute myocardial infarction and unstable angina in Switzerland (AMIS Plus)

Summary

Objectives: To evaluate the in-hospital outcome of STEMI (ST elevation myocardial infarction) patients admitted to Swiss hospitals between 2000 and December 2007, and to identify the predictors of in-hospital mortality and major cardiac events.

Methods: Data from the Swiss national registry AMIS Plus (Acute Myocardial Infarction and Unstable Angina in Switzerland) were used. All patients admitted between January 2000 and December 2007 with STEMI or a new LBBB (left bundle branch block) were included in the registry.

Result: We studied 12,026 STEMI patients admitted to 68 hospitals. The mean age was 64 ± 13 years and 73% of the patients were male. Incidence of in-hospital death was 7.6% in 2000 and 6% in 2007. Reinfarction fell from 3.7% in 2000 to 0.9% in 2007. Thrombolysis decreased from 40.2% in 2000 to 2% in 2007. Clinical predictors of mortality were: age >65 years, Killips class III or IV, diabetes, Q wave myocardial infarction (at presentation). Patients undergoing percutaneous coronary intervention (PCI) had lower mortality and reinfarction rates (3.9% versus 11.2% and 1.1% versus 3.1% respectively, p <0.001) over time, although their numbers increased from 43% in 2000 to 85% in 2007. Patients admitted to hospitals with PCI facilities had lower mortality than patients hospitalised in hospitals without it, but the demographic characteristics differ widely between the two groups.

Both in-hospital mortality and reinfarction decreased significantly over the time, parallel to an increased number of PCI. PCI was also the strongest predictor of survival.

Conclusion: In-hospital mortality and reinfarction rate have decreased significantly in Swiss STEMI patients in the last seven years, parallel to a significant increase in the number of percutaneous coronary interventions in addition to medical therapy. Outcome is not related to the site of admission but to PCI access.

Key words: myocardial infarction; angioplasty, STEMI, PCI

Introduction

Reperfusion and prompt restoration of antegrade coronary blood flow results in myocardial salvage and improved left ventricular function and survival [1–3] of patients with acute myocardial infarction. Both thrombolytic therapy and percutaneous coronary intervention (PCI) are used to open the infarct-related artery [4–6]. Several randomised trials favour PCI over thrombolysis [7–16], especially in high risk patients [11, 17] due to a higher patency rate, less reocclusion, recurrent

No conflict of interest to declare.
ischaemia, reinfarction, and stroke [18–21]. Thrombolysis and medical management remain the first choice treatment in some hospitals without PCI capabilities, because of strategic constraints. Previous studies have shown that on site PCI is a major determinant of patient management. However, it is still an open question whether the outcome of patients admitted to hospitals with or without PCI capability is the same or not, merely because the strategy and the infrastructure are different.

We evaluated the Swiss STEMI (ST elevation myocardial infarction) patients over time to detect change in management (in line with the evolving guidelines) and possibly in their prognosis. We also evaluated the clinical predictors of in-hospital mortality, reinfarction and stroke.

Methods

Data from the Swiss national registry on myocardial infarction AMIS Plus were used.

The AMIS Plus Registry

Since 1997 this Swiss prospective national registry has collected data from patients admitted with a definitive diagnosis of acute coronary syndrome in Switzerland (AMIS Plus). It is a prospective data bank monitored by a Data Centre (Institute of Social and Preventive Medicine at the University of Zürich) providing blinded data of Swiss STEMI and non-STEMI patients. It is a complete cohort of Swiss patients. Data are collected by an internet- and/or paper-based questionnaire of 140 questions, related to patient history, clinical parameters, previous medical history, laboratory parameters, in-hospital and discharge treatment, hospitalisation outcome and destination at discharge. The questionnaire is completed by physicians and research nurses and has been described previously [22].

Patients are enrolled in the registry on the basis of final diagnosis, which must comply with one of the following three definitions: acute myocardial infarction (symptoms or ECG changes compatible with acute coronary syndrome, or both, and cardiac enzymes (total creatine kinase (CK) or CK-MB) at least twice the upper limit of normal range); acute coronary syndrome with minimum necrosis (symptoms or ECG changes compatible with acute coronary syndrome, or both, and cardiac enzymes (total CK or CK-MB) lower than twice the upper limit of normal range); acute coronary syndrome with mini-

Results

Baseline characteristics

Patient demographics and characteristics are presented in table 1. A total of 12,026 patients (73% male) with a mean age of 64 ± 13 years were treated for STEMI and included in the database. In-hospital mortality was 6.9%, reinfarction 1.9% and stroke 1% (table 2). The incidence of death, reinfarction and stroke declined significantly over time from 7.6% in 2000 to 6.5% (p = 0.004) in 2007 for mortality, and from 3.7% to 1% (p <0.001) for reinfarction. The incidence of stroke decreased over time from 1.8% in 2000 to
The AMIS Plus registry is a unique ongoing multicentre project assessing management of acute coronary syndromes in Switzerland. In-hospital mortality and incidence of reinfarction decrease significantly as the number of PCI rises. This confirms the benefit of aggressive management of STEMI patients. In-hospital mortality was 6.9%, which is comparable with other European registries (7% mortality in the Euro Heart survey and GRACE [26, 27], 10.4% by MINAP [28], 14% for the Danish registry [29]). Classical clinical predictors of mortality were as in previous trials [30]. As expected, reperfusion (thrombolysis and PCI) was associated with a better outcome. We confirm the impact of PCI facilities on reperfusion strategies. Availability of a catheterisation laboratory will of course favour the use of primary PCI, with some benefit to the outcome. Our findings are in agreement with other observational studies.

0.8% in 2007 (p = 0.04). The percentage of patients treated by PCI increased from 43% to attain the high percentage of 85% in 2007.

Patient management is shown in figure 1. Medical treatment without reperfusion was used in 20%, thrombolysis alone in 7%, primary PCI in 65% and PCI in addition to thrombolysis (facilitated PCI) in 8%. Patients admitted to hospitals without PCI facilities were more prone to receive thrombolysis (23% versus 9%) than those admitted to hospitals with PCI facilities. PCI was more often used in hospitals with PCI facilities in 2000 (67% versus 27%) but this difference was reduced in 2007 (94% versus 71%). Mortality and reinfarction rate were higher in hospitals without catheterisation facilities (table 2), although the population was not fully comparable (mean age 65 ± 11 years versus 63 ± 13 years (p <0.001).

The use of thrombolysis fell from 40.2% in 2000 to 2% in 2007.

Multivariable analysis for in-hospital death and MACE are presented in tables 3 and 4. Age >65, diabetes, Killip class III-IV, Q wave MI (at presentation) and no PCI were the most significant predictors of death and MACE.

Site of hospitalisation (in-house PCI facilities or not) is not a predictor of death (OR 1.1, 95% CI 0.9–1.3) or MACE (OR 0.9, 95% CI 0.8–1.1). Other variables entered (see the statistics section) were not significant predictors.

The difference in mortality and reinfarction is not related to the hospital type but to access to PCI. Reperfusion (PCI and thrombolysis) have a significant positive impact on survival.

### Discussion

The AMIS Plus registry is a unique ongoing multicentre project assessing management of acute coronary syndromes in Switzerland. In-hospital mortality and incidence of reinfarction decrease significantly as the number of PCI rises. This confirms the benefit of aggressive management of STEMI patients. In-hospital mortality was 6.9%, which is comparable with other European registries (7% mortality in the Euro Heart survey and GRACE [26, 27], 10.4% by MINAP [28], 14% for the Danish registry [29]). Classical clinical predictors of mortality were as in previous trials [30]. As expected, reperfusion (thrombolysis and PCI) was associated with a better outcome. We confirm the impact of PCI facilities on reperfusion strategies. Availability of a catheterisation laboratory will of course favour the use of primary PCI, with some benefit to the outcome. Our findings are in agreement with other observational studies.

### Table 1

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>N</th>
<th>12026</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>8828</td>
<td>(73%)</td>
</tr>
<tr>
<td>Mean age</td>
<td>64 ± 13 years</td>
<td></td>
</tr>
<tr>
<td>Killip I-II</td>
<td>11130</td>
<td>(93%)</td>
</tr>
<tr>
<td>Killip III-IV</td>
<td>845</td>
<td>(7%)</td>
</tr>
<tr>
<td>Q waves (at admission)</td>
<td>1971</td>
<td>(16.8%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6200</td>
<td>(54.7%)</td>
</tr>
<tr>
<td>History of CAD</td>
<td>5155</td>
<td>(40.2%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2128</td>
<td>(18.5%)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>4711</td>
<td>(41.7%)</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>5873</td>
<td>(54.9%)</td>
</tr>
</tbody>
</table>

CAD: coronary heart disease

### Table 2

<table>
<thead>
<tr>
<th>Patients outcome</th>
<th>All hospitals</th>
<th>Hospitals without 24 h PCI on site</th>
<th>Hospitals with 24 h PCI on site</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospitality mortality</td>
<td>6.9%</td>
<td>8.3%</td>
<td>5.8%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Reinfarction</td>
<td>1.9%</td>
<td>2.8%</td>
<td>1.3%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Stroke</td>
<td>1.1%</td>
<td>0.9%</td>
<td>1.2%</td>
<td>0.104</td>
</tr>
</tbody>
</table>

Figure 1

Management of patients.

Figure 2

Evolution of PCI, mortality and reinfarction from 2000 to 2007.

<table>
<thead>
<tr>
<th>Year</th>
<th>PCI</th>
<th>Mortality</th>
<th>Reinfarction</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>120</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>2001</td>
<td>130</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>2002</td>
<td>140</td>
<td>15</td>
<td>7</td>
</tr>
<tr>
<td>2003</td>
<td>150</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>2004</td>
<td>160</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>2005</td>
<td>170</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>2006</td>
<td>180</td>
<td>22</td>
<td>11</td>
</tr>
<tr>
<td>2007</td>
<td>190</td>
<td>24</td>
<td>12</td>
</tr>
</tbody>
</table>


Males 8828 (73%)
Mean age 64 ± 13 years
Killip I-II 11130 (93%)
Killip III-IV 845 (7%)
Q waves (at admission) 1971 (16.8%)
Hypertension 6200 (54.7%)
History of CAD 5155 (40.2%)
Diabetes 2128 (18.5%)
Current smoker 4711 (41.7%)
Dyslipidaemia 5873 (54.9%)
CAD: coronary heart disease

Table 1

Baseline characteristics.

Table 2

Patients outcome.
Table 3
Multivariate analysis of predictors of death.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI</td>
<td>0.3</td>
<td>0.4–0.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>0.7</td>
<td>0.5–0.9</td>
<td>0.008</td>
</tr>
<tr>
<td>Killip III-IV</td>
<td>8.3</td>
<td>6.7–10.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age &gt;65 years</td>
<td>3.6</td>
<td>2.8–4.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.5</td>
<td>1.2–1.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LBBB</td>
<td>1.3</td>
<td>1.0–1.7</td>
<td>0.043</td>
</tr>
<tr>
<td>Q waves</td>
<td>1.3</td>
<td>1.0–1.6</td>
<td>0.030</td>
</tr>
<tr>
<td>&gt;6 h delay</td>
<td>0.8</td>
<td>0.6–1.0</td>
<td>0.022</td>
</tr>
</tbody>
</table>

Table 4
Multivariate analysis of the composite end point predictors of major adverse cardiac events (death, reinfarction, stroke).

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI</td>
<td>0.6</td>
<td>0.5–0.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>0.8</td>
<td>0.6–1.0</td>
<td>0.037</td>
</tr>
<tr>
<td>Age &gt;65 years</td>
<td>2.8</td>
<td>2.1–3.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Killip III-IV</td>
<td>6.9</td>
<td>5.7–8.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Q waves</td>
<td>1.5</td>
<td>1.2–1.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.5</td>
<td>1.2–1.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LBBB</td>
<td>1.2</td>
<td>1.0–1.6</td>
<td>0.083</td>
</tr>
<tr>
<td>&gt;6 h delay</td>
<td>0.9</td>
<td>0.7–1.0</td>
<td>0.128</td>
</tr>
</tbody>
</table>

In essence the AMIS Plus is an observational registry; patients were not randomised to institutions with or without cardiac catheterisation facilities. It is recorded on a voluntary basis and may have been a cause of undetected bias.

Our analysis suffers the limitations of multivariable evaluation, designed to correct raw results according to differences in baseline characteristics.

Correspondence:
Dr. V. Stolt Steiger
Division of cardiology
Hôpital Cantonal
CH-1700 Fribourg
Switzerland
E-Mail: valerie.stolt@turnover.ch

References

7 Andersen HR, Nielsen TT, Rasmussen K, for the DANAMI-2 Investigators. Comparison of Coronary Angioplasty with Fibri


14 Zijlstra F, Patel A, Jones M. Clinical characteristics and outcomes of patients with early (≤2 h), intermediate (2–4) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23:350–7.


